Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy

ALK+ aNSCLC treatment expectations now and in the future

Date

15 Sep 2024

Session

Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Tony S.K. Mok

Authors

T.S.K. Mok

Author affiliations

  • Clinical Oncology Department, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin/HK

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introduction

Presenter: Tony S.K. Mok

Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy

Resources:

Webcast

Meeting close

Presenter: Tony S.K. Mok

Session: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.